GlaxoSmithKline plc’s (GSK) “Buy” Rating Reiterated at HSBC Holdings plc

HSBC Holdings plc restated their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a report issued on Wednesday, Marketbeat.com reports. The brokerage currently has a GBX 1,970 ($25.44) price target on the stock.

GSK has been the subject of a number of other reports. Shore Capital reaffirmed a hold rating on shares of GlaxoSmithKline plc in a research report on Friday, July 28th. Liberum Capital reaffirmed a buy rating and set a GBX 1,900 ($24.54) target price on shares of GlaxoSmithKline plc in a research report on Wednesday, August 30th. J P Morgan Chase & Co reaffirmed a neutral rating on shares of GlaxoSmithKline plc in a research report on Monday, July 24th. S&P Global set a GBX 1,500 ($19.37) target price on GlaxoSmithKline plc and gave the company a sell rating in a research report on Wednesday, July 26th. Finally, Credit Suisse Group decreased their target price on GlaxoSmithKline plc from GBX 1,775 ($22.92) to GBX 1,725 ($22.28) and set a neutral rating for the company in a research report on Wednesday, September 6th. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of Hold and an average price target of GBX 1,705.90 ($22.03).

Shares of GlaxoSmithKline plc (LON GSK) opened at 1454.00 on Wednesday. GlaxoSmithKline plc has a 52 week low of GBX 1,446.50 and a 52 week high of GBX 1,745.56. The company has a 50-day moving average price of GBX 1,507.18 and a 200 day moving average price of GBX 1,610.52. The stock’s market capitalization is GBX 71.07 billion.

COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline plc’s (GSK) “Buy” Rating Reiterated at HSBC Holdings plc” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/16/glaxosmithkline-plcs-gsk-buy-rating-reiterated-at-hsbc-holdings-plc.html.

The business also recently disclosed a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be issued a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, August 10th. This represents a dividend yield of 1.23%.

In related news, insider Manvinder Singh Banga acquired 2,267 shares of the firm’s stock in a transaction dated Wednesday, July 26th. The stock was acquired at an average price of GBX 1,599 ($20.65) per share, with a total value of £36,249.33 ($46,815.61). Also, insider Patrick Vallance acquired 861 shares of the firm’s stock in a transaction dated Friday, July 14th. The stock was bought at an average cost of GBX 1,618 ($20.90) per share, with a total value of £13,930.98 ($17,991.71). In the last three months, insiders bought 3,152 shares of company stock valued at $5,055,023.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply